Citation Relationships

Sasidharakurup H, Melethadathil N, Nair B, Diwakar S (2017) A Systems Model of Parkinson's Disease Using Biochemical Systems Theory. OMICS 21:454-464 [PubMed]

   A systems model of Parkinson’s disease using biochemical systems theory (Sasidharakurup et al. 2017)

References and models cited by this paper

References and models that cite this paper

Atack CV (1973) The determination of dopamine by a modification of the dihydroxyindole fluorimetric assay. Br J Pharmacol 48:699-714 [PubMed]

Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152:879-84 [PubMed]

Beal MF (1996) Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol 6:661-6 [PubMed]

Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-6 [Journal] [PubMed]

Braatz EM, Coleman RA (2015) A mathematical model of insulin resistance in Parkinson's disease. Comput Biol Chem 56:84-97 [Journal] [PubMed]

Bromek E, Haduch A, Golembiowska K, Daniel WA (2011) Cytochrome P450 mediates dopamine formation in the brain in vivo. J Neurochem 118:806-15 [Journal] [PubMed]

Burré J, Sharma M, Südhof TC (2015) Definition of a molecular pathway mediating a-synuclein neurotoxicity. J Neurosci 35:5221-32 [Journal] [PubMed]

Cardoso SM, Moreira PI, Agostinho P, Pereira C, Oliveira CR (2005) Neurodegenerative pathways in Parkinson's disease: therapeutic strategies. Curr Drug Targets CNS Neurol Disord 4:405-19 [PubMed]

Cedillos RO (2013) a-Synuclein aggregates activate the Nlrp3 inflammasome following vesicle rupture Master's Thesis, 1859. Loyola University. Chicago, IL

Clayton DF, George JM (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21:249-54 [PubMed]

Conway KA, Harper JD, Lansbury PT (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4:1318-20 [Journal] [PubMed]

Eisenhofer G, Aneman A, Friberg P, Hooper D, Fåndriks L, Lonroth H, Hunyady B, Mezey E (1997) Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 82:3864-71 [Journal] [PubMed]

Eliezer D, Kutluay E, Bussell R, Browne G (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307:1061-73 [Journal] [PubMed]

Eriksen J, Jørgensen TN, Gether U (2010) Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J Neurochem 113:27-41 [Journal] [PubMed]

Fahn S (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 991:1-14 [PubMed]

Falkenburger BH, Schulz JB (2006) Limitations of cellular models in Parkinson's disease research. J Neural Transm Suppl :261-8 [PubMed]

Farrer MJ (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 7:306-18 [Journal] [PubMed]

Fink AL (1998) Protein aggregation: Folding aggregates, inclusion bodies and amyloid Fold Des 3:9-23

Funahashi A,Matsuoka Y,Jouraku A,Kitano H,Kikuchi N (2006) Celldesigner: A modeling tool for biochemical networks Proceedings of the 38th Conference on Winter Simulation, Monterey, CA :1707-1712

Geddes JW (2005) alpha-Synuclein: a potent inducer of tau pathology. Exp Neurol 192:244-50 [Journal] [PubMed]

Gendron TF, Petrucelli L (2009) The role of tau in neurodegeneration. Mol Neurodegener 4:13 [Journal] [PubMed]

Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300:636-40 [Journal] [PubMed]

GREENFIELD JG, BOSANQUET FD (1953) The brain-stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry 16:213-26 [PubMed]

Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:112-9 [Journal] [PubMed]

Hiroi T, Imaoka S, Funae Y (1998) Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 249:838-43 [Journal] [PubMed]

Houghton D,Hurtig H (2013) Parkinson's Disease: Medications

Iljina M, Garcia GA, Horrocks MH, Tosatto L, Choi ML, Ganzinger KA, Abramov AY, Gandhi S, Wood NW, Cremades N, Dobson CM, Knowles TP, Klenerman D (2016) Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading. Proc Natl Acad Sci U S A 113:E1206-15 [Journal] [PubMed]

Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62:389-97 [PubMed]

Kahle PJ, Haass C (2004) How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep 5:681-5 [Journal] [PubMed]

Kim WS, Kågedal K, Halliday GM (2014) Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther 6:73 [Journal] [PubMed]

Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI (2010) Tau protein: relevance to Parkinson's disease. Int J Biochem Cell Biol 42:1775-8 [Journal] [PubMed]

Levy OA, Malagelada C, Greene LA (2009) Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 14:478-500 [Journal] [PubMed]

LIPKIN LE (1959) Cytoplasmic inclusions in ganglion cells associated with parkinsonian states: a neurocellular change studied in 53 cases and 206 controls. Am J Pathol 35:1117-33 [PubMed]

Longo GS, Pinhel MA, Gregório ML, Oliveira BA, Quinhoneiro DC, Tognola WA, Oliveira FN, Martins DP, Cezario SM, Sado CL, Nakazone MA, Calastri MC, Souza DR (2015) Alpha-synuclein A53T mutation is not frequent on a sample of Brazilian Parkinson's disease patients. Arq Neuropsiquiatr 73:506-9 [Journal] [PubMed]

Lotharius J, Brundin P (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3:932-42 [Journal] [PubMed]

Marques O, Outeiro TF (2012) Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis 3:e350 [Journal] [PubMed]

Masters JM, Noyce AJ, Warner TT, Giovannoni G, Proctor GB (2015) Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity. Parkinsonism Relat Disord 21:1251-5 [Journal] [PubMed]

Meiser J, Weindl D, Hiller K (2013) Complexity of dopamine metabolism. Cell Commun Signal 11:34 [Journal] [PubMed]

Mellick GD, Siebert GA, Funayama M, Buchanan DD, Li Y, Imamichi Y, Yoshino H, Silburn PA, Hattori N (2009) Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism Relat Disord 15:105-9 [Journal] [PubMed]

Oczkowska A,Lianeri M,Kozubski W,Dorszewska J (2014) Mutations of PARK genes and a-synuclein and Parkin concentrations in Parkinson's disease A Synopsis of Parkinson's Disease, Rana AQ, ed. pp.1

Parkinson J (2002) An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 14:223-36; discussion 222 [Journal] [PubMed]

Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22:3090-9 [Journal] [PubMed]

Ramanan VK, Saykin AJ (2013) Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. Am J Neurodegener Dis 2:145-75 [PubMed]

Rao RV, Bredesen DE (2004) Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr Opin Cell Biol 16:653-62 [Journal] [PubMed]

Sahay S, Ghosh D, Dwivedi S, Anoop A, Mohite GM, Kombrabail M, Krishnamoorthy G, Maji SK (2015) Familial Parkinson disease-associated mutations alter the site-specific microenvironment and dynamics of a-synuclein. J Biol Chem 290:7804-22 [Journal] [PubMed]

Sass MB, Lorenz AN, Green RL, Coleman RA (2009) A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease. J Neurosci Methods 178:366-77 [Journal] [PubMed]

Sato S, Cerny RL, Buescher JL, Ikezu T (2006) Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J Neurochem 98:1573-84 [Journal] [PubMed]

Schapira AH (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7:97-109 [Journal] [PubMed]

Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-7 [PubMed]

Sharpless NS, Tyce GM, Thal LJ, Waltz JM, Tabaddor K, Wolfson LI (1981) Free and conjugated dopamine in human ventricular fluid. Brain Res 217:107-18 [PubMed]

Shulman JM, De Jager PL, Feany MB (2011) Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 6:193-222 [Journal] [PubMed]

Sidhu A, Wersinger C, Moussa CE, Vernier P (2004) The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann N Y Acad Sci 1035:250-70 [Journal] [PubMed]

Singh Dolt K, Hammachi F, Kunath T (2017) Modeling Parkinson's disease with induced pluripotent stem cells harboring a-synuclein mutations. Brain Pathol 27:545-551 [Journal] [PubMed]

Sipos I, Tretter L, Adam-Vizi V (2003) Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals. J Neurochem 84:112-8 [PubMed]

Speed NK (2010) The role of insulin signaling on dopamine transporter trafficking. Doctoral dissertation, Vanderbitt University, Nashville, TN

Sulzer D (2001) alpha-synuclein and cytosolic dopamine: stabilizing a bad situation. Nat Med 7:1280-2 [Journal] [PubMed]

Tretter L, Adam-Vizi V (2004) Generation of reactive oxygen species in the reaction catalyzed by alpha-ketoglutarate dehydrogenase. J Neurosci 24:7771-8 [Journal] [PubMed]

Wellstead P,Cloutier M (2009) A systems approach to Parkinson's disease

Wenya W (2011) Inhibition of Tau phosphorylation as a potential strategy in treatment of Parkinson's disease Towards New Therapies for Parkinson's Disease, Finkelstein D, ed. pp.151

Werner-Allen JW, DuMond JF, Levine RL, Bax A (2016) Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of a-Synuclein. Angew Chem Int Ed Engl 55:7374-8 [Journal] [PubMed]

Wersinger C, Prou D, Vernier P, Niznik HB, Sidhu A (2003) Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Mol Cell Neurosci 24:91-105 [PubMed]

Wersinger C, Sidhu A (2003) Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci Lett 340:189-92 [PubMed]

Yamamori H, Khatoon S, Grundke-Iqbal I, Blennow K, Ewers M, Hampel H, Iqbal K (2007) Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification. Neurosci Lett 418:186-9 [Journal] [PubMed]

Yeager MP, Coleman RA (2010) In silico evidence for glutathione- and iron-related pathogeneses in Parkinson's disease. J Neurosci Methods 188:151-64 [Journal] [PubMed]

Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM (2000) Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A 97:13354-9 [Journal] [PubMed]

(65 refs)